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Previewscell viability were more strongly affected
by thapsigargin in T-ALL lines with HD
mutations in Notch1 than those carrying
wild-type Notch1. Moreover, significant
on-target antileukemia effects with no
gastrointestinal toxicity were observed in
two independent human T-ALL xenograft
models carrying HD mutations. The lack
of gut toxicity indicates that sufficient
levels of wild-type Notch1 and Notch2
receptors reached the surface in the
presence of SERCA inhibitors, whereas
oncogenic Notch molecules were selec-
tively and effectively prevented from
exiting the ER.
Why would SERCA inhibition preferen-
tially affect the maturation and activity of
mutant receptors? Roti et al. (2013) spec-
ulate that the reason may reflect folding
defects in many of the activating HD
mutations identified in T-ALL (Malecki
et al., 2006). SERCA inhibitors exploit
this impaired folding and block matu-
ration of the mutant receptor (Fig-
ure 1B). Alternatively or simultaneously,
the mutant Notch1 proteins themselves
trigger ER stress, making the cells more
sensitive to the increase in ER stressinduced by thapsigargin treatment,
leading to enhanced clearance of mutant
Notch proteins. Regardless of the under-
lying mechanism, these studies provide a
therapeutic window for targeting SERCA
as an antileukemia strategy for many
T-ALL patients harboring mutations in
the NRR.
While promising, many challenges
remain before translating this strategy to
the clinic. Given the fundamental role of
calcium in normal physiology and the
pleiotropic roles of Notch in tissue
maintenance and cancer suppression
(South et al., 2012), targeted delivery of
SERCA inhibitors to T-ALL cells would
be desirable. This was achieved with
delivery of modified thapsigargin to
human cancer xenografts (Denmeade
et al., 2012). Even if thapsigargin can be
specifically targeted, T-ALL may contain
cells refractory to treatment, having lost
the NRR or gained activating Myc muta-
tions. Perhaps the most beneficial use
for thapsigargin will be in combinatorial
therapies aimed to combat T-ALL at its
earliest manifestation before additional
mutations are gained.Cancer Cell 2REFERENCES
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WNT/b-catenin signaling is critical to the development of many cancer types. A paper by Mo and colleagues
in a recent issue of Cell shows that autocrine CXCL12/CXCR4 chemokine signaling activates b-catenin
signaling in a rare peripheral nerve sarcoma. Together with the availability of small molecules targeting
CXCR4, this finding suggests new avenues for cancer therapy.It is exciting to link established signaling
pathways. It is especially provocative
when compounds designed to targetone molecule for a specific disease are
shown to have potential in a novel
context. In a recent issue ofCell, the labo-ratories of Luis Parada and Lu Le accom-
plish just this by showing that a pathway
that was first identified as relevant to3, March 18, 2013 ª2013 Elsevier Inc. 269
Figure 1. Canonical WNT Signaling and CXCR4 Activation of b-Catenin
In canonical WNT signaling (left of dotted line), WNT ligands activate FRIZZLED receptors; LRP and LGR
are co-receptors. Receptor activation leads through inactivation of GSK3b to stabilization of b-catenin.
Stabilized b-cateninmoves to the nucleus and activates gene transcription. Mo et al. (2013) (right of dotted
line) describe a novel mechanism in which MPNST tumor cells secrete CXCL12 ligand, activate CXCR4
receptors, and, via AKT, inactivate GSK3b and stabilizing b-catenin.
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Previewslymphocyte chemotaxis is also a driver of
human Schwann cell tumor progression
(Mo et al., 2013). The authors go on to
find that this pathway acts via another
pathway that was initially identified
in organismal development and found
to be corrupted in many cancers. The
paper links the CXCR4 cell surface che-
mokine receptor, via autocrine CXCL12
ligand production, to the Wnt/b-catenin
signaling pathway in malignant peripheral
nerve sheath tumors (MPNSTs) (Mo et al.,
2013). CXCR4 antagonists are being
intensively investigated, because CXCR4
is a co-receptor for HIV on T cells, and
early stage clinical studies show that
blocking CXCR4 delays the onset
of AIDS in HIV infected individuals
(Domanska et al., 2013). The work by Mo
et al. (2013) suggests that CXCR4 antago-
nists may be useful to treat MPNSTs,
a peripheral nerve related soft tissue270 Cancer Cell 23, March 18, 2013 ª2013 Esarcoma with very poor prognosis, espe-
cially when they occur in the context of
neurofibromatosis type 1 (NF1) disease
(Widemann, 2009). In MPNST, inactiva-
tion of the NF1 gene, which encodes
a GTPase activating protein for Ras
proteins, increases Ras signaling with
activation of the key downstream signal-
ing pathways MEK, AKT, and mTOR (De
Raedt et al., 2011; Jessen et al., 2013).
The paper by Mo et al. (2013) also shows
expression of CXCR4 and Wnt/b-catenin
pathway components in benign neurofi-
bromas, which can be MPNST precursor
lesions.
The WNT/b-catenin signaling pathway
was identified for its roles in development
and controls critical processes in worms
to mammals, from the formation of teeth
to the control of stem cells in the intestine
(reviewed in Clevers and Nusse, 2012).
Despite >7,000 papers on WNT/b-cateninlsevier Inc.signaling listed in the PubMed database,
this pathway had not been directly impli-
cated in MPNSTs. In the cells from which
MPNSTs derive, which may be neural
crest cells, skin-derived precursors, and/
or committed Schwann cells, WNT/b-cat-
enin signaling normally regulates cell fate
decisions and transiently suppresses full
differentiation (myelination) in Schwann
cells, potentially explaining a role in
tumor progression by differentiation block
(Lewallen et al., 2011; Hari et al., 2012).
Canonical WNT/b-catenin signaling
(Figure 1) plays a role in many types of
cancer, including colorectal, lung, breast,
ovarian, prostate, liver, and brain tumors
(Clevers and Nusse, 2012; Saito-Diaz
et al., 2013). b-catenin-dependent tran-
scription can promote cell cycle pro-
gression, stem cell self-renewal, and
epithelial-to-mesenchymal transition.
WNT signaling in cancer can be aberrantly
activated by activation of mutations in
b-catenin (CTNNB1), overexpression of
WNT ligand genes, inactivation of muta-
tions in destruction complex genes (i.e.,
AXIN1, GSK3B, and APC), or promoter
hypermethylation of negative regulators
of WNT signaling (Saito-Diaz et al.,
2013). Activation of the PI3K/AKT
signaling pathway, either by the loss of
PTEN or through activation of upstream
tyrosine kinase receptors, also causes
phosphorylation and inactivation of
GSK3b, stabilizing b-catenin (Clevers
and Nusse, 2012). In the study by Mo
et al. (2013), WNT signaling is activated
by crosstalk with the CXCL12/CXCR4
signaling, downstream of AKT (Figure 1).
CXCL12 (SDF-1) is a chemokine.
CXCL12 binding to the heterotrimeric
G protein-coupled receptor CXCR4 is,
like b-catenin signaling, required for
normal development. In many situations,
stromal cells secrete CXCL12 and attract
cells expressing CXCR4 receptors. In this
fashion, immune cells are attracted to
sites of inflammation and hematopoietic
cells home to the bone marrow. This
paracrine CXCL12/CXCR4 pathway has
been exploited therapeutically; CXCR4
blockade facilitates the removal of cells
from the bone marrow niche for use in
transplantation (reviewed in Domanska
et al., 2013). CXCL12/CXCR4 paracrine
signaling is also relevant to tumor metas-
tasis when tumor cells expressing CXCR4
migrate toward distant sites where ligand
is produced (Domanska et al., 2013).
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PreviewsThe paper by Mo et al. (2013) shows
that autocrine, rather than paracrine,
CXCL12 promotes tumor cell prolifera-
tion. The notion that tumor cells can
manufacture, secrete, and respond to
their own CXCL12 was discovered in
prostate tumors by Sun et al. (2003). Mo
et al. (2013) use antibodies against
CXCL12 and CXCR4 receptor blockade,
both of which decreaseMPNST cell prolif-
eration. Furthermore, whereas CXCR4
activation can recruit endothelial cells to
promote neoangiogenesis, vessel density
remains the same after CXCR4 blockade,
providing additional evidence that the
tumor cell effects are cell autonomous.
CXCL12 produced in a paracrine manner
by host tumor stromal cells, as in other
forms of cancer, may also contribute to
effects on tumor growth.
The authors show that CXCR4 activa-
tion in MPNST cells activates b-catenin
by AKT-mediated phosphorylation and
inactivation of GSK3b, thus stabilizing
b-catenin (Figure 1). How CXCR4 acti-
vates AKT is not entirely clear. This may
occur through the bg subunits of
CXCR4, known to indirectly activate AKT
(Domanska et al., 2013). The authors
exclude roles for activation of NF-kB,
RAS/MAPK, and JAK/STAT3. Additional
pathways downstream of CXCR4 might
also contribute to b-catenin stabilization.
CXCR4 is known to activate SRC family
kinases, C-CBL, and RHO GTPases
(Domanska et al., 2013), which may be
relevant. b-catenin activation likely also
requires additional genetic events or the
activation of signaling pathways in neuro-
fibromas and MPNSTs, particularly in
MPNSTs that develop in the absence of
NF1 syndrome. This is because many
MPNSTs express b-catenin, but do notexpress CXCR4. Also, many neurofi-
bromas express CXCR4, but not
b-catenin.
Themolecular mechanisms that explain
CXCL12 and CXCR4 expression in
MPNST cells also remain undefined.
One possibility is that CXCR4/CXCL12
expression reflects the embryonic neural
crest origin of MPNST cells. The authors
demonstrate that CXCR4 expression
frequency and intensity are especially
pronounced in neurofibromas and
MPNSTs associated with NF1 disease.
Therefore, signaling downstream of NF1
may normally suppress expression of
CXCL12/CXCR4.
Despitemany efforts to identify drugs to
target b-catenin signaling, no inhibitor
has, to date, demonstrated the appro-
priate pharmacodynamic and pharmaco-
kinetic properties to be used as a drug
for the treatment of cancer patients. In
this light, it is impressive that the authors
have shown that the CXCR4 inhibitor
AMD3100 inhibits b-catenin signaling
in vitro and in vivo. With AMD3100
(Plerixafor; FDA approved for use in
hematopoietic stem cell mobilization)
currently in clinical testing in many
settings, it should be feasible to test in
human MPNST patients. Mo et al. (2013)
show a clear delay in MPNST formation
in human xenografts and also in a geneti-
cally engineered mouse model. Certainly,
targeting the CXCR4 receptor alone is
insufficient to halt MPNST growth or
shrink tumors; the authors show that the
main effect is proliferation arrest. More-
over, the authors note that some tumors
expressed CXCR4 in a patchy manner,
where the cells are not all positive. For
both of these reasons, tumor ablation is
likely to require co-therapy, perhaps withCancer Cell 2identified NF1/Ras pathway inhibitors
(De Raedt et al., 2011; Jessen et al.,
2013). Especially because NF1 mutations
have been identified in many types of
cancer, it will be exciting to discover those
that use the CXCL12/CXCR4 pathway to
activate Wnt/b-catenin signaling and
those that may benefit from CXCR4
blockade.REFERENCES
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